MarketPulse
S

$SGIOY

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Bioversys Ag

BioVersys to Showcase Late-Stage Antibiotic Pipeline at ESCMID 2026

BioVersys will present Phase 3 data for BV100 and collaborate data for BV500 at ESCMID 2026, advancing its antibiotic-resistant infection pipeline.
SGIOYPhase 3 clinical trialantimicrobial resistance
GlobeNewswire Inc.GlobeNewswire Inc.··Bioversys Ag

BioVersys Bolsters NTM Pipeline via Hackensack Meridian Ansamycin Partnership

BioVersys expands NTM pipeline through exclusive ansamycin chemistry partnership with Hackensack Meridian Health, strengthening BV500 program with Shionogi.
SGIOYclinical-stage biopharmaceuticalantimicrobial resistance
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma Co., Ltd.

Nxera Pharma Pursues South Korea Insomnia Market With Daridorexant Filing

Nxera Pharma seeks South Korean approval for insomnia drug daridorexant, already marketed globally, with expected 2027 regulatory decision.
SGIOYPhase 3 trialregulatory approval